AstraZeneca to Acquire EsoBiotec

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.

AstraZeneca to Acquire Gracell Biotechnologies (FasTCAR CAR-T) for Up to $1.2 Billion

December 27, 2023

Healthcare Services

AstraZeneca entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharmaceutical company focused on autologous cell therapies for cancer and autoimmune diseases. The deal is expected to close in the first quarter of 2024 and includes Gracell’s FasTCAR-enabled dual-targeting CAR-T therapy GC012F, with an upfront value of about $1.0 billion and total transaction value of up to about $1.2 billion including a contingent value right tied to a regulatory milestone.

AstraZeneca (Alexion) Acquires Amolyt Pharma for Up to $1.05 Billion

March 14, 2024

Biotechnology

Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases, entered into a definitive agreement to be acquired by AstraZeneca’s Rare Disease business (Alexion) for $800 million upfront plus up to $250 million in regulatory milestone contingent payments. The total deal value is up to $1.05 billion and is expected to close by the end of Q3 2024, subject to customary closing conditions and regulatory clearances.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

Ipsen Acquires Epizyme to Expand Oncology Portfolio

August 12, 2022

Pharmaceuticals

Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.